Definitive Healthcare (NASDAQ:DH) Shares Down 1.5%

Definitive Healthcare Corp. (NASDAQ:DH) shares dropped 1.5% on Wednesday . The stock traded as low as $5.34 and last traded at $5.35. Approximately 144,979 shares changed hands during mid-day trading, a decline of 80% from the average daily volume of 737,135 shares. The stock had previously closed at $5.43.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Barclays lowered their price target on Definitive Healthcare from $11.00 to $7.00 and set an “equal weight” rating for the company in a research report on Thursday, May 9th. Needham & Company LLC reiterated a “hold” rating on shares of Definitive Healthcare in a report on Wednesday, May 8th. William Blair restated an “outperform” rating on shares of Definitive Healthcare in a research note on Tuesday, May 14th. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Definitive Healthcare from $10.00 to $7.00 and set a “hold” rating on the stock in a research note on Thursday, May 9th. Finally, Stifel Nicolaus decreased their target price on shares of Definitive Healthcare from $11.00 to $9.50 and set a “buy” rating for the company in a research report on Wednesday, May 8th. Nine investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Definitive Healthcare presently has a consensus rating of “Hold” and a consensus target price of $9.94.

Definitive Healthcare Stock Down 1.5 %

The firm has a market capitalization of $630.95 million, a PE ratio of -3.06, a price-to-earnings-growth ratio of 3.95 and a beta of 1.30. The company has a quick ratio of 2.30, a current ratio of 2.30 and a debt-to-equity ratio of 0.20. The business has a 50-day moving average price of $5.77 and a 200-day moving average price of $7.68.

Definitive Healthcare (NASDAQ:DH) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.04). Definitive Healthcare had a negative net margin of 78.16% and a positive return on equity of 0.51%. The firm had revenue of $63.48 million for the quarter, compared to analyst estimates of $64.00 million. Equities research analysts forecast that Definitive Healthcare Corp. will post 0.1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Definitive Healthcare

A number of institutional investors have recently made changes to their positions in the stock. Conestoga Capital Advisors LLC raised its holdings in shares of Definitive Healthcare by 1.3% in the 1st quarter. Conestoga Capital Advisors LLC now owns 5,595,627 shares of the company’s stock valued at $45,157,000 after buying an additional 74,490 shares during the period. Vanguard Group Inc. increased its stake in Definitive Healthcare by 1.5% during the first quarter. Vanguard Group Inc. now owns 4,535,377 shares of the company’s stock worth $36,600,000 after purchasing an additional 67,068 shares during the period. Massachusetts Financial Services Co. MA increased its stake in Definitive Healthcare by 76.0% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 3,466,514 shares of the company’s stock worth $34,457,000 after purchasing an additional 1,496,652 shares during the period. Raymond James & Associates lifted its position in shares of Definitive Healthcare by 41.6% during the first quarter. Raymond James & Associates now owns 844,814 shares of the company’s stock worth $6,818,000 after purchasing an additional 248,266 shares in the last quarter. Finally, Comerica Bank boosted its stake in shares of Definitive Healthcare by 9.3% in the first quarter. Comerica Bank now owns 436,831 shares of the company’s stock valued at $3,525,000 after purchasing an additional 37,044 shares during the period. 98.67% of the stock is currently owned by institutional investors and hedge funds.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.